While HLA donor-specific antibodies (DSAs) are the primary mediators of allograft rejection, 20-30% of antibody-mediated rejection (ABMR) episodes occur in their absence. These 'DSA-negative' rejections represent a significant clinical challenge. This review explores the role of non-HLA antibodies (n-HLab) as potential markers of unexplained graft injury. Pathophysiologically, ischemia-reperfusion injury and endothelial stress trigger the release of cryptic autoantigens, transforming the allograft into a source of self-antigens. Key targets include AT1R, ETAR, LG3, vimentin, and MICA. While observational studies show an association between these antibodies and severe vascular rejection, a causal link and the therapeutic impact of their removal remain undefined. Currently, there is no definitive evidence that monitoring or therapeutically targeting n-HLab translates into improved long-term clinical outcomes. Diagnosis is currently limited by a lack of standardized assays and consensus thresholds. Management remains largely empirical. In conclusion, while n-HLab represent a promising area for risk stratification, further research and clinical validation are required before their routine implementation in clinical practice can be recommended.
Ratbi et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: